Hybryte™ flash study selected as a 'top poster' winner for presentation at the national organization for rare disorders' rare diseases and orphan products breakthrough summit

Princeton, n.j., oct. 12, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a "top abstract winner" and has been accepted for display and presentation at the 2021 national organization for rare disorders (nord) rare diseases and orphan products breakthrough summit to be held virtually on october 18-19, 2021.
SNGX Ratings Summary
SNGX Quant Ranking